Fabrizio Di Maida

Dr. Fabrizio Di Maida

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
Anna Julie PeiredAnna Julie Peired
Anna Julie Peired
GAGiulia Antonelli
Giulia Antonelli
MAMaria Lucia Angelotti
Maria Lucia Angelotti
MAMarco Allinovi
Marco Allinovi
FGFrancesco Guzzi
Francesco Guzzi
PRPaola Romagnani
Paola Romagnani
Papillary renal cell carcinoma derives from renal progenitors in an adenoma-carcinoma sequence, and acute kidney injury is a preventable risk factor.

1 January 2021 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
Fabrizio Di MaidaFabrizio Di Maida
Fabrizio Di Maida
GCGianmartin Cito
Gianmartin Cito
LLLuca Lambertini
Luca Lambertini
FVFrancesca Valastro
Francesca Valastro
GMGirolamo Morelli
Girolamo Morelli
Andrea CocciAndrea Cocci
Andrea Cocci
Di Maida F, et al. World J Mens Health. 2020 Jan;38:e34. https://doi.org/10.5534/wjmh.200065

Verified
Journal Article
Open access
PDF file
DLDaniele Lavacchi
Daniele Lavacchi
EPElisa Pellegrini
Elisa Pellegrini
VPValeria Emma Palmieri
Valeria Emma Palmieri
LDLaura Doni
Laura Doni
MMMarinella micol Mela
Marinella micol Mela
LALorenzo Antonuzzo
Lorenzo Antonuzzo
Systemic treatment of renal cancer (RCC) has undergone remarkable changes over the past 20 years with the introduction of immunotherapeutic agents targeting programmed cell death (PD-1)/programmed death-ligand 1 (PD-L1) axis, as a single-agent or combined with anti-CTLA-4 monoclonal antibodies (MoAbs) or a multi-target vascular endothelial growth factor-(VEGF) tyrosine kinase inhibitor (TKI). In this paper, we review the main evidence on the use of Immune Checkpoint Inhibitors (ICIs) for RCC treatment from the first demonstration of activity of a nivolumab single agent in a phase I trial to the novel combination strategies (anti-PD-1 plus anti-CTLA4 or anti-PD-1 plus TKI). In addition, we discuss the use of anti-PD-1/PD-L1 agents in patients with non-clear cells and rare histological subtype RCC. Then, we critically examine the current findings in biomarkers that have been proposed to be prognostic or predictive to the response of immunotherapy including immune gene expression signature, B7-H1 expression, PBRM1 loss of function, PD-L1 expression, frame shift indel count, mutations in bromodomain-containing genes in patients with MiT family translocation RCC (tRCC), high expression of the T-effector gene signature, and a high myeloid inflammation gene expression pattern. To date, a single biomarker as a predictor of response has not been established. Since the dynamic behavior of the immune response and the different impact of ICI treatment on patients with specific RCC subtypes, the integration of multiple biomarkers and further validation in clinical trials are needed.

1 November 2021 in Journal of Endourology
Verified
Journal Article
Closed access
ATAgostino Tuccio
Agostino Tuccio
AGAntonio Andrea Grosso
Antonio Andrea Grosso
FSFrancesco Sessa
Francesco Sessa
MSMatteo Salvi
Matteo Salvi
Riccardo TelliniRiccardo Tellini
Riccardo Tellini
AMAndrea Minervini
Andrea Minervini
Background: Holmium laser enucleation of the prostate (HoLEP) is considered a safe and effective treatment in case of bladder outlet obstruction (BOO). Despite technical execution has evolved over time, from the standard three-lobes to the more recent en-bloc approaches, data comparing these two techniques are missing. The aim of the present study was to describe our en-bloc HoLEP with early apical release technique and compare peri- and postoperative results with the classical three-lobe approach in a single referral center. Materials and Methods: We prospectively analyzed all consecutive cases between 2017 and 2019 divided according to the type of approach. Patients were preoperatively studied through instrumental assessment and clinical evaluation, using validated questionnaires and then postoperatively at specific time frames. Linear regression analysis was performed to evaluate possible predictor of continuous variables. All the procedures were carried out by one single expert surgeon. Results: Overall, 168 patients were included, of which 81 were treated with classical three-lobes and 87 with en-bloc with early apical release technique. The two cohorts were comparable related to preoperative features and postoperative complication rate. Mean enucleation time (ET), lasing time, amount of energy delivered, and overall operative time were significantly lower in en-bloc procedures ( p < 0.05). Stepwise multivariable linear regression showed that en-bloc strategy can significantly predict shorter ET and lower energy delivered. Stress incontinence rate at 1-month follow-up was found to be significantly reduced in the en-bloc group, compared with the counterpart. Conclusions: Both techniques are effective and safe treatment options for BOO, since peri- and postoperative surgical and functional outcomes were favorable. En-bloc strategy may significantly decrease ET and the amount of energy delivered leading to a reduced early stress incontinence rate compared with the standard approach.

1 December 2018 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
AMAndrea Minervini
Andrea Minervini
RCRiccardo Campi
Riccardo Campi
Fabrizio Di MaidaFabrizio Di Maida
Fabrizio Di Maida
Andrea MariAndrea Mari
Andrea Mari
IMIlaria Montagnani
Ilaria Montagnani
MCMarco Carini
Marco Carini

19 October 2023 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
AGAntonio Andrea Grosso
Antonio Andrea Grosso
DADaniele Amparore
Daniele Amparore
Fabrizio Di MaidaFabrizio Di Maida
Fabrizio Di Maida
SCSabrina de Cillis
Sabrina de Cillis
Andrea CocciAndrea Cocci
Andrea Cocci
ATAgostino Tuccio
Agostino Tuccio